CRISPR Therapeutics AG (NASDAQ: CRSP) on Tuesday, soared 2.70% from the previous trading day, before settling in for the closing price of $45.55. Within the past 52 weeks, CRSP’s price has moved between $30.04 and $63.68.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company achieved an average annual earnings per share of -25.48%. With a float of $82.79 million, this company’s outstanding shares have now reached $86.36 million.
In an organization with 393 employees, it is important to assess its efficiency. In terms of profitability, gross margin is -239.71%, operating margin of -1282.72%, and the pretax margin is -1032.03%.
CRISPR Therapeutics AG (CRSP) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of CRISPR Therapeutics AG is 4.14%, while institutional ownership is 69.15%. The most recent insider transaction that took place on May 29 ’25, was worth 141,316. In this transaction Chief Medical Officer of this company sold 3,932 shares at a rate of $35.94, taking the stock ownership to the 6,068 shares. Before that another transaction happened on Mar 21 ’25, when Company’s Chief Executive Officer sold 10,031 for $41.23, making the entire transaction worth $413,578. This insider now owns 195,085 shares in total.
CRISPR Therapeutics AG (CRSP) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around -25.48% per share during the next fiscal year.
CRISPR Therapeutics AG (NASDAQ: CRSP) Trading Performance Indicators
CRISPR Therapeutics AG (CRSP) is currently performing well based on its current performance indicators. A quick ratio of 15.64 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 107.25.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -4.52, a number that is poised to hit -1.43 in the next quarter and is forecasted to reach -4.46 in one year’s time.
Technical Analysis of CRISPR Therapeutics AG (CRSP)
Let’s dig in a bit further. During the last 5-days, its volume was 3.47 million. That was better than the volume of 2.24 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 76.16%.
During the past 100 days, CRISPR Therapeutics AG’s (CRSP) raw stochastic average was set at 64.78%, which indicates a significant decrease from 90.88% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 39.75% in the past 14 days, which was lower than the 63.34% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $38.87, while its 200-day Moving Average is $43.10. However, in the short run, CRISPR Therapeutics AG’s stock first resistance to watch stands at $47.69. Second resistance stands at $48.59. The third major resistance level sits at $49.43. If the price goes on to break the first support level at $45.95, it is likely to go to the next support level at $45.11. Assuming the price breaks the second support level, the third support level stands at $44.21.
CRISPR Therapeutics AG (NASDAQ: CRSP) Key Stats
Market capitalization of the company is 4.04 billion based on 86,364K outstanding shares. Right now, sales total 37,310 K and income totals -366,250 K. The company made 870 K in profit during its latest quarter, and -136,000 K in sales during its previous quarter.
